1. Introduction {#sec1-jcm-07-00069}
===============

Diabetes is a major threat to humans affecting over 400 million people across the globe \[[@B1-jcm-07-00069]\]. Among the diabetic cases, the majority are due to type 2 diabetes (T2D) \[[@B1-jcm-07-00069]\]. Several factors predispose people to T2D, among which obesity constitutes a major risk factor and is highly associated with the disease \[[@B2-jcm-07-00069]\]. According to a WHO global report, over 650 million people were obese in 2016 \[[@B3-jcm-07-00069]\]. On the other hand, obesity is usually associated with dyslipidaemia, a major lipid abnormality characterised by increased levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), and reduced level of high density lipoprotein (HDL). Dyslipidaemia is highly prevalent and associated with T2D. Hypertriglyceridaemia, a component of dyslipidaemia, is known to be the principal lipid abnormality that promotes insulin resistance \[[@B4-jcm-07-00069]\]. Hypertriglyceridaemia is responsible for increased production and decreased clearance of lipoproteins leading to increased levels of free fatty acids (FFA) in the blood stream \[[@B5-jcm-07-00069],[@B6-jcm-07-00069]\].

In a healthy and non-diabetic state, insulin promotes triglyceride storage in adipocytes and prevents lipolysis and release of FFAs. Peroxisome proliferator activated receptor protein (PPAR) is one of the molecules which regulate triglyceride storage in adipocytes. *PPAR* is a nuclear receptor ligand-activated transcription factor commonly expressed in adipose tissue, liver, and heart \[[@B7-jcm-07-00069]\]. The gene exists in three isoforms namely; *PPAR-α*, *PPARβ/δ*, and *PPAR-γ*. *PPAR-γ* has been shown to be the isoform that is functionally related to diabetes \[[@B8-jcm-07-00069]\] as it plays a major role in glucose metabolism, differentiation of adipocytes, regulation of lipid metabolism, promotion of insulin sensitivity, and has beneficial effects on plasma lipids \[[@B9-jcm-07-00069],[@B10-jcm-07-00069]\]. Synthetic ligands of *PPAR-γ* such as rosiglitazone and pioglitazone have been reported to facilitate increased serum HDL and reduced plasma triglyceride levels \[[@B11-jcm-07-00069]\].

Several polymorphisms have been identified in the *PPAR-γ2* gene \[[@B12-jcm-07-00069]\]. The most important is the Pro12Ala polymorphism on exon B of the *PPAR-γ2* gene. This polymorphism is defined by a CCA to GCA mutation on codon 12 changing a proline (Pro) to an alanine (Ala) \[[@B13-jcm-07-00069]\]. Previous studies have shown the *Ala* allele to confer reduced risk of diabetes development among ethnic groups, such as Japanese-Americans \[[@B14-jcm-07-00069],[@B15-jcm-07-00069]\]. The frequency of *Ala* allele among Asians and Africans is low (1--3%) with most individuals having the *Pro12* allele \[[@B16-jcm-07-00069]\]. Though an expanding body of evidence reports the relationship between the Pro12Ala polymorphism of the *PPARγ2* gene and T2D and/or obesity in some African populations \[[@B17-jcm-07-00069],[@B18-jcm-07-00069],[@B19-jcm-07-00069]\], none of these studies assessed the polymorphism within a Nigerian population.

2. Materials and Methods {#sec2-jcm-07-00069}
========================

2.1. Study Population and Design {#sec2dot1-jcm-07-00069}
--------------------------------

This study was part of an ongoing case-control study involving T2D and non-diabetic (ND) patients at Enugu State University Teaching Hospital (ESUTH) in Enugu, Nigeria. Ethical approval was obtained from the ethical committee at ESUTH and the study was conducted in accordance with the Helsinki Declaration. Written informed consent was obtained from all patients before recruitment into the study. Patients above 30 years of age, who have not eaten for the past 12 h (overnight fasting), without any critical or emergency health conditions or complications and not admitted at the hospital were recruited for the study. Breastfeeding and/or pregnant women as well as HIV positive patients were excluded from the study. T2D patients were those with at least a one-year history of the disease, diagnosed according to the International Diabetic Federation (IDF) criteria \[[@B20-jcm-07-00069]\]. ND patients, who served as the control, were those without hyperglycaemia or diabetes.

2.2. Data Collection and Laboratory Analysis {#sec2dot2-jcm-07-00069}
--------------------------------------------

Demographic information of patients including age and sex was obtained while the systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using an automatic sphygmomanometer. Height, weight, and waist circumference (WC) of the patients were measured and the Body Mass index (BMI) calculated. WC and BMI were used to classify obesity according to WHO standard. After interview, 2 mL of blood was collected from each patient, transferred into EDTA free tubes and the fasting blood sugar (FBS) was measured using an Accucheck glucometer (Roche Diabetes Care, Inc., Burgess Hill, UK) according to the glucose oxidase enzymatic method by Trinder \[[@B21-jcm-07-00069]\]. Blood samples were then centrifuge at 5000 rpm for 10 min and serum was obtained for the determination of TC, TG, LDL, and HDL using diagnostic kits from Randox Laboratories Ltd. (Co Antrim, UK) following the manufacturer's recommended procedure. TC was determined according to the enzymatic method of Allain et al. \[[@B22-jcm-07-00069]\], TG was assayed as described by Esders and Michira \[[@B23-jcm-07-00069]\] and HDL was quantified by the precipitation method of Grove \[[@B24-jcm-07-00069]\]. LDL was calculated using the Freidwald's \[[@B25-jcm-07-00069]\] formula: LDL = TC − (TG/5) − HDL.

2.3. Genotyping of PPARγ2 Pro12Ala Variant {#sec2dot3-jcm-07-00069}
------------------------------------------

DNA was extracted using GeneJET Genomic DNA Purification kit (K0721, Thermo Fisher Scientific Inc., Waltham, MA, USA). Extracted DNA samples were amplified by PCR and analyzed for Pro12Ala polymorphism of the *PPARγ2* gene by restriction fragment length polymorphism-PCR (RFLP-PCR). The PCR amplification was carried out using the forward (5′-GCCAATTCAAGCCCAGTC-3′) and the reverse (5′-GATATGTTTGCAGACAGTGTATC-3′) primers. The PCR reaction mixture contained 12 µL of OneTaq Quick-Load 2X Master Mix with standard buffer (New England Biolabs, Ipswich, MA, USA), 4 µL of each primer (40 uM), and 8 µL of DNA sample (\<10 ng) making a total volume of 28 µL. The reaction was carried out under the following conditions: Initial denaturation at 95 °C for 15 min, followed by 34 cycles of denaturation at 95 °C for 1 min, annealing at 56 °C for 1 min and elongation at 72 °C for 1 min, with a final extension at 72 °C for 10 min. The PCR product was visualised in a UV transilluminator (Bio Olympics, Ltd., Thousand Oaks, CA, USA) after electrophoresis on a 2% agarose gel to confirm the presence of the *PPARγ2* gene. Positive PCR products were digested overnight with *Bst* UI restriction enzyme at 37 °C. The reaction mixture was set to a final volume of 20 µL containing 10 µL of amplicon, 0.4 μL of the *Bst* UI (NEB), 2 µL of 10× smartcut buffer (NEB) and 8 µL of sterile water. The digested products were separated by electrophoresis on a 3% agarose gel.

2.4. Statistical Analysis {#sec2dot4-jcm-07-00069}
-------------------------

Data were analyzed using Statistical Package for Social Science (SPSS version 16; IBM Analytics, Armonk, NY, USA.). Results were expressed as mean ± Standard Error of Mean (S.E.M). Parametric independent sample *t*-test was used to compare mean differences of the demographic and clinical characteristics such as obesity (BMI and WC) and lipid profile indices (TC, TG, HDL, and LDL) between T2D patients and ND patients. A *p*-value less than 0.05 was considered statistically significant.

3. Results {#sec3-jcm-07-00069}
==========

3.1. Baseline Characteristic of Participants {#sec3dot1-jcm-07-00069}
--------------------------------------------

One hundred and forty-eight (148) subjects participated in the study. Among these subjects, 73 (49.3%) were T2D patients while 75 (50.7%) were ND patients (control). The demographic and clinical characteristics of the patients are summarized in [Table 1](#jcm-07-00069-t001){ref-type="table"}. FBS as well as the weight were significantly higher (*p* \< 0.05) in T2D patients compared with their non-diabetic counterparts while the height, DBP and SBP did not show any significant differences between T2D patients and non-diabetic controls.

3.2. Obesity and Lipid Profile Indices of Patients {#sec3dot2-jcm-07-00069}
--------------------------------------------------

BMI and WC were significantly higher (*p* \< 0.05) in T2D patients compared to the control ([Table 2](#jcm-07-00069-t002){ref-type="table"}). Similarly, TC, TG, and LDL levels were significantly higher (*p* \< 0.05) in T2D patients. HDL level was significantly lower (*p* \< 0.05) in T2D patients compared to non-diabetic participants. The prevalence of obesity (based on BMI and WC) was significantly higher (*p* \< 0.05) in T2D patients compared to non-diabetic control participants. Moreover, the prevalence of lipid abnormalities (dyslipidaemia) characterized by hypercholesterolaemia (TC \> 200 mg/dL), hypertriglyceridaemia (TG \> 150 mg/dL), high HDL (\>100 mg/dL), and low HDL (\<50 mg/dL) was significantly greater (*p* \< 0.001) in T2D patients compared to non-diabetic patients.

3.3. Genotyping for PPARγ2 Pro12Ala Polymorphism {#sec3dot3-jcm-07-00069}
------------------------------------------------

The expected DNA fragment of the *PPARγ2* gene after PCR amplification was 270 bp. After a restriction digest, an electrophoretic band of 270 bp was observed for all samples indicating the presence of the homozygous wild-type Pro/Pro genotype which lacks a restriction site ([Figure 1](#jcm-07-00069-f001){ref-type="fig"}) while the mutant homozygous Ala/Ala genotype which has a restriction site was absent as no sample showed band sizes of 227 and 43 bp. Also, the heterozygote Pro/Ala genotype was absent in the study population. As such, the Ala12 variant was totally absent from the study population.

4. Discussion {#sec4-jcm-07-00069}
=============

T2D which constitutes about 90% to 95% of all diabetic cases is increasingly on the rise in Africa \[[@B26-jcm-07-00069]\]. This disease has become a major public health problem of concern in Nigeria as recent data has shown Nigeria to have the highest disease burden in the continent of Africa. Incidence of obesity, one of the major risk factors of T2D, and diabetic dyslipidaemia are also on the increase in Nigeria \[[@B3-jcm-07-00069]\]. The important role of *PPARγ2* in the regulation of lipid metabolism coupled with the reported association between *PPARγ* polymorphisms and T2D \[[@B15-jcm-07-00069],[@B27-jcm-07-00069],[@B28-jcm-07-00069]\] further necessitate the investigation of changes in the *PPARγ2* gene among diabetic patients in Nigeria. The Ala variant of the *PPARγ* gene is known to improve insulin sensitivity by altering transcriptional activities and expression of *PPAR-γ* in adipocytes, thereby suppressing lipolysis and release of FFAs while enhancing insulin's action \[[@B29-jcm-07-00069],[@B30-jcm-07-00069]\]. Though the Pro12Ala variant has shown to be associated with T2D and obesity in various populations across the globe \[[@B17-jcm-07-00069]\], such findings are yet to be revealed in Nigeria. Thus, the Pro12Ala polymorphism and its association with T2D was investigated in this study. Our finding revealed the presence of the homozygous Pro/Pro genotype in all participants; both diabetic and non-diabetic patients, and complete absence of the homozygous Ala/Ala and heterozygous Pro/Ala genotypes. As such, the *Pro12* allele was 100% present while the *Ala12* allele was totally absent in the population. This finding concurs with previous findings in Cameroon which also showed a complete absence of the *Ala12* allele \[[@B20-jcm-07-00069]\] and in Ghana with only one participant having the *Ala12* allele in more than a thousand participants (\<0.001%) \[[@B31-jcm-07-00069]\]. This confirms the findings of previous studies which have shown Pro12Ala polymorphism to have a very low frequency (\<3%) in populations of African ancestry (African-Americans) \[[@B15-jcm-07-00069],[@B16-jcm-07-00069]\] as well as in typical black Africans population in South Africa and Ethiopian Africans \[[@B17-jcm-07-00069]\]. Cameroon, Ghana, and Nigeria, which present similar genetic profiles, all belong to the Sub-Saharan region of Africa suggesting that areas with similar ethnicity selects particular genetic trait. As such, the prevalence of the *Ala12* allele may vary widely across various ethnic populations. The Caucasian population has been shown to have the highest frequency of this polymorphism with almost 25%, followed by Native Americans with about 10%. Other ethnic populations such as the Japanese, South American, Indian, and Chinese present a frequency less than 4% \[[@B14-jcm-07-00069],[@B15-jcm-07-00069]\]. Findings from this present study may therefore suggest that the *Pro* allele may be the wild type which originated from the African descendants particularly from Sub-Saharan Africa and the *Ala* allele as the mutant type which may have emerged through evolution and environmental changes as the native Africans migrated to other parts of the world.

A recent meta-analysis study showed the *PPAR-γ2* Pro12Ala polymorphism to be associated with obesity risk, suggesting that the *Ala* allele could increase obesity susceptibility particularly in Caucasian and Asian populations \[[@B32-jcm-07-00069]\]. Thus, it was also of interest to investigate the influence of the Pro12Ala polymorphism on obesity and lipid abnormalities in T2D subjects. Though obesity indices (BMI and WC) were significantly higher (*p* \< 0.05) in T2D patients compared to the control and also, dyslipidaemia characterised by elevated TC, TG, and LDL levels and reduced HDL was significantly present (*p* \< 0.05) in T2D patients, the complete absence of the *Ala12* allele in the population limited the assessment of the influence of this polymorphic variant on obesity and lipid abnormalities among T2D subjects.

5. Conclusions {#sec5-jcm-07-00069}
==============

The *Ala* mutant allele of *PPAR-γ2* was absent in this study and thus the Pro12Ala *PPAR-γ2* polymorphism may not be associated with obesity and/or T2D in this population. However, obesity and dyslipidaemia were associated with T2D. Our finding confirms previous findings around the sub-Sahara region and other African ethnic group which have shown *Ala12* allele to be totally absent or have a very low frequency in African populations.
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![RFLP-PCR of *PPARγ2* Pro12Ala Polymorphism. Samples were analyzed on a 3% agarose gel after restriction digest. D01--D03 = Samples for diabetic patients; ND01--ND03 = Samples for non-diabetic patients; UD = Undigested sample (control); MWM = Molecular weight marker.](jcm-07-00069-g001){#jcm-07-00069-f001}

jcm-07-00069-t001_Table 1

###### 

Baseline and clinical characteristics of participants.

  Characteristics   T2D Patients     ND Patients     *p*-Value
  ----------------- ---------------- --------------- -----------
  Age (years)       56.83 ± 1.21     49.03 ± 1.89    0.001
  Height (m)        1.58 ± 0.01      1.61 ± 0.01     0.179
  Weight (kg)       78.85 ± 3.42     71.52 ± 1.95    0.043
  SBP (mmHg)        132.69 ± 2.65    132.86 ± 3.23   0.967
  DSP (mmHg)        78.80 ± 1.36     81.76 ± 2.24    0.240
  FBS (mg/dL)       166.71 ± 11.39   65.75 ± 3.79    0.000

Values are presented as Mean ± S.E.M. Age, weight and FBS are significantly higher (*p* \< 0.05) in T2D patients. SBP = Systolic blood pressure; DSP = Diastolic blood pressure; FBS = Fasting blood sugar.

jcm-07-00069-t002_Table 2

###### 

Comparison of obesity and lipid abnormalities in patients.

  Parameter       T2D Patients      *n* (%)      ND Patients     *n* (%)      *p*-Value
  --------------- ----------------- ------------ --------------- ------------ -----------
  BMI (Kg/m^2^)   31.38 ± 1.41      31 (21.1)    27.81 ± 0.76    22 (15.0)    0.026
  WC (cm)         100.15 ± 1.70     53 (36.1)    89.37 ± 2.25    32 (21.8)    \<0.001
  TC (mg/dL)      291.78 ± 28.90    58 (39.4)    159.43 ± 7.77   11 (7.5)     \<0.001
  TG (mg/dL)      241.33 ± 15.443   60 (40.8)    148.82 ± 7.59   31 (21.1)    \<0.001
  LDL (mg/dL)     212.40 ± 29.42    41 (27.8)    78.96 ± 7.96    9 (6.2)      \<0.001
  HDL (mg/dL)     33.55 ± 2.14      45 (30.6%)   62.74 ± 5.16    25 (17.0%)   \<0.001

Values are presented as Mean ± S.E.M. *n* = the number of patients and prevalence (%) of obesity based on BMI and WC or number of patients with lipid abnormalities based on TC, TG, LDL, and HDL. BMI = Body mass index; WC = Waist circumference; TC = total cholesterol; TG = triglyceride; LDL = Low density lipoprotein; HDL = High density lipoprotein.
